Authors
Issa S Al-Amri, Samira Farhadi, Mazen M Jamil Al-Obaidi, Abdulaziz Y AlKindi, Waleed Al Rajhi, Saad Sabbar Dahham
Published in
Current molecular medicine. Oct 02, 2026. Epub Oct 02, 2026.
Abstract
Ursolic acid, a naturally occurring pentacyclic triterpenoid, has been extensively investigated in preclinical studies for its anticancer effects. Although numerous studies have described its interaction with individual molecular targets, how these pathways function together in a coordinated manner is still not fully understood. This review examines available mechanistic studies to better understand how UA interacts with multiple cancer-related pathways.
A literature search was conducted using PubMed, Scopus, Web of Science, and Google Scholar. Studies were selected based on their relevance to underlying mechanisms and overall study quality.
UA has been reported to affect several cancer-related processes, including apoptosis, angiogenesis, and cell cycle regulation. It can activate both intrinsic and extrinsic apoptotic pathways, inhibit angiogenesis through modulation of VEGF and HIF-1α, and interfere with Epithelial-Mesenchymal Transition (EMT) by regulating MMP-2 and MMP-9. In addition, UA influences key signaling pathways such as PI3K/ Akt/mTOR, MAPK/ERK, STAT3, and NF-κB.
These findings suggest that UA may act through multiple mechanisms, although their clinical relevance remains unclear.
UA modulates multiple interconnected oncogenic pathways involved in apoptosis, angiogenesis, cell-cycle regulation, and metastasis. However, current evidence remains predominantly preclinical, and further pharmacokinetic optimization together with well-designed clinical studies is required before its therapeutic potential can be translated into clinical practice.
PMID:
42861807
Bibliographic data and abstract were imported from PubMed on 12 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0